Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWest China Hospital
About this trial
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients who underwent liver resection
patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Disqualifiers
patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
patients diagnosed with other specific types of sarcomas;
patients with concurrent other malignancies during the course of PHSC;
patients who were lost to follow-up or lacked essential clinical data.
Trial population
The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
postoperative adjuvant therapy
Procedure/SurgeryGiven the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy1 intervention
Group B: Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy0 interventions
Trial outcomes
Primary outcomes
1
Disease-free survival
Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.
Time frame
From December 2018 to May 2023Secondary outcomes
1
Overall survival
Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.
Time frame
From December 2018 to May 2023Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov